Free Trial

Fortress Biotech (FBIO) Competitors

Fortress Biotech logo
$1.73 +0.03 (+1.76%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.72 -0.01 (-0.52%)
As of 05/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FBIO vs. SGMO, IRWD, ACHV, DOMH, AGEN, CRIS, SABS, BOLT, MTEM, and AMGN

Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Dominari (DOMH), Agenus (AGEN), Curis (CRIS), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), and Amgen (AMGN). These companies are all part of the "biotechnology" industry.

Fortress Biotech vs.

Sangamo Therapeutics (NASDAQ:SGMO) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Sangamo Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 810.01%. Fortress Biotech has a consensus target price of $21.00, suggesting a potential upside of 1,113.87%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Sangamo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sangamo Therapeutics
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Sangamo Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

In the previous week, Sangamo Therapeutics had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 9 mentions for Sangamo Therapeutics and 4 mentions for Fortress Biotech. Sangamo Therapeutics' average media sentiment score of 0.99 beat Fortress Biotech's score of -0.22 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sangamo Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fortress Biotech has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$63.76M1.81-$257.83M-$0.39-1.27
Fortress Biotech$57.78M0.89-$60.64M-$2.23-0.78

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of -84.53% compared to Sangamo Therapeutics' net margin of -257.87%. Fortress Biotech's return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sangamo Therapeutics-257.87% -264.16% -107.24%
Fortress Biotech -84.53%N/A -34.93%

Sangamo Therapeutics received 129 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.69% of users gave Fortress Biotech an outperform vote while only 62.69% of users gave Sangamo Therapeutics an outperform vote.

CompanyUnderperformOutperform
Sangamo TherapeuticsOutperform Votes
457
62.69%
Underperform Votes
272
37.31%
Fortress BiotechOutperform Votes
328
63.69%
Underperform Votes
187
36.31%

Summary

Fortress Biotech beats Sangamo Therapeutics on 11 of the 18 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBIO vs. The Competition

MetricFortress BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$51.16M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.579.0626.7319.70
Price / Sales0.89251.66389.54120.67
Price / CashN/A65.8538.2534.62
Price / Book17.306.456.764.50
Net Income-$60.64M$143.98M$3.23B$248.22M
7 Day Performance-4.42%0.38%0.43%-0.78%
1 Month Performance8.81%2.14%9.07%11.53%
1 Year Performance-5.98%-0.33%18.56%8.99%

Fortress Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBIO
Fortress Biotech
1.7014 of 5 stars
$1.73
+1.8%
$21.00
+1,113.9%
-7.5%$51.16M$57.78M-0.57170News Coverage
Analyst Revision
SGMO
Sangamo Therapeutics
1.9041 of 5 stars
$0.75
+7.1%
$5.17
+588.9%
-22.2%$171.90M$57.80M-1.00480Analyst Forecast
IRWD
Ironwood Pharmaceuticals
4.5187 of 5 stars
$0.73
+3.5%
$4.78
+551.9%
-90.4%$118.74M$351.41M-24.46220Positive News
ACHV
Achieve Life Sciences
2.093 of 5 stars
$2.48
+5.5%
$14.33
+478.0%
-42.3%$86.02MN/A-2.1920Positive News
Gap Up
DOMH
Dominari
1.0862 of 5 stars
$5.87
-2.0%
N/A+113.5%$85.96M$18.15M-1.524News Coverage
Analyst Downgrade
AGEN
Agenus
3.8547 of 5 stars
$3.50
+20.3%
$8.75
+150.0%
-68.2%$74.10M$103.46M-0.31440Analyst Upgrade
High Trading Volume
CRIS
Curis
3.0568 of 5 stars
$1.96
+3.7%
$21.00
+971.4%
-81.6%$20.51M$10.91M-0.2560Analyst Revision
Gap Up
SABS
SAB Biotherapeutics
2.855 of 5 stars
$1.98
+10.6%
$11.40
+475.8%
-32.9%$18.39M$2.24M-0.54140High Trading Volume
BOLT
Bolt Biotherapeutics
3.2445 of 5 stars
$0.37
+3.4%
$1.13
+204.1%
-57.5%$14.19M$7.69M-0.2290Analyst Forecast
MTEM
Molecular Templates
N/AN/AN/AN/A$1,000.00$23.48M0.00260
AMGN
Amgen
4.3708 of 5 stars
$274.76
+3.3%
$310.23
+12.9%
-12.1%$147.74B$34.13B36.3925,200Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:FBIO) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners